Endoscopic ultrasound-guided fine-needle aspiration plus KRAS and GNAS mutation in malignant intraductal papillary mucinous neoplasm of the pancreas

 

 Permissions and Reprints

Background: KRAS and GNAS mutations are common in intraductal papillary mucinous neoplasia of the pancreas (IPMN). The aims of this study were to assess the role of pre-therapeutic cytopathology combined with KRAS and GNAS mutation assays within cystic fluid sampled by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) to predict malignancy of IPMN.

Patients and methods: We prospectively included 37 IPMN patients with clinical and/or imaging predictors of malignancy (men: 24; mean age: 69.5 years). Cytopathology (performed on cystic fluid and/or IPMN nodules), KRAS (Exon 2, codon 12) and GNAS (Exon 8, codon 201) mutations assays (using TaqMan^® allelic discrimination) were performed on EUS-FNA material. The final diagnosis was obtained from IPMN resections (n = 18); surgical biopsies, EUS-FNA analyses, and follow-up (n = 19): 10 and 27 IPMN were benign and malignant, respectively.

Results: Sensitivity, specificity, positive and negative predictive values, and accuracy of cytopathology alone to diagnose IPMN malignancy were 55 %, 100 %, 100 %, 45 %, and 66 %, respectively. When KRAS-mutation analysis was combined with cytopathology these values were 92 %, 50 %, 83 %, 71 %, and 81 %, respectively. GNAS assays did not improve the performances of cytopathology alone or those of cytopathology plus a KRAS assay.

Conclusions: In patients with a likelihood of malignant IPMN at pre-therapeutic investigation, testing for KRAS mutations in cystic fluid sampling by EUS-FNA improved the results of cytopathology for the diagnosis of malignancy whereas GNAS mutation assay did not.

• References

• 1 Tanaka M, Chari S, Adsay V et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6: 17-32
  CrossrefPubMedGoogle Scholar
• 2 Tanaka M, Fernández-del Castillo C, Adsay V et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12: 183-197
  CrossrefPubMedGoogle Scholar
• 3 Nagai K, Doi R, Kida A et al. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection. World J Surg 2008; 32: 271-278
  CrossrefPubMedGoogle Scholar
• 4 Sadakari Y, Ienaga J, Kobayashi K et al. Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules. Pancreas 2010; 39: 232-236
  CrossrefPubMedGoogle Scholar
• 5 Kanno A, Satoh K, Hirota M et al. Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas. J Gastroenterol 2010; 45: 952-959
  CrossrefPubMedGoogle Scholar
• 6 Hwang DW, Jang JY, Lee SE et al. Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution. Langenbecks Arch Surg 2012; 397: 93-102
  CrossrefPubMedGoogle Scholar
• 7 Mimura T, Masuda A, Matsumoto I et al. Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas. J Clin Gastroenterol 2010; 44: e224-229
  CrossrefPubMedGoogle Scholar
• 8 Arlix A, Bournet B, Otal P et al. Long-term clinical and imaging follow-up of nonoperated branch duct form of intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2012; 41: 295-301
  CrossrefPubMedGoogle Scholar
• 9 Anand N, Sampath K, Wu BU. Cyst features and risk of malignancy in itraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 913-921
  CrossrefPubMedGoogle Scholar
• 10 Sugiyama M, Izumisato Y, Abe N et al. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 2003; 90: 1244-1249
  CrossrefPubMedGoogle Scholar
• 11 Bournet B, Kirzin S, Carrère N et al. Clinical fate of branch duct and mixed forms of intraductal papillary mucinous neoplasia of the pancreas. J Gastroenterol Hepatol 2009; 24: 1211-1217
  CrossrefPubMedGoogle Scholar
• 12 Daudé M, Muscari F, Buscail C et al. Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol 2015; 21: 2658-2667
  CrossrefPubMedGoogle Scholar
• 13 Salvia R, Fernández-del Castillo C, Bassi C et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004; 239: 678-685
  CrossrefPubMedGoogle Scholar
• 14 Ogura T, Masuda D, Kurisu Y et al. Potential predictors of disease progression for main-duct intraductal papillary mucinous neoplasms of the pancreas. J Gastroenterol Hepatol 2013; 28: 1782-1786
  CrossrefPubMedGoogle Scholar
• 15 Wang H, Chen T, Wang H et al. A systematic review of the Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity and its Portsmouth modification as predictors of post-operative morbidity and mortality in patients undergoing pancreatic surgery. Am J Surg 2013; 205: 466-472
  CrossrefPubMedGoogle Scholar
• 16 Rockacy M, Khalid A. Update on pancreatic cyst fluid analysis. Ann Gastroenterol 2013; 26: 122-127
  PubMedGoogle Scholar
• 17 Suzuki R, Thosani N, Annangi S et al. Diagnostic yield of EUS-FNA-based cytology distinguishing malignant and benign IPMNs: a systematic review and meta-analysis. Pancreatology 2014; 14: 380-384
  CrossrefPubMedGoogle Scholar
• 18 Maker AV, Carrara S, Jamieson NB et al. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg 2015; 220: 243-253
  CrossrefPubMedGoogle Scholar
• 19 Nissim S, Idos GE, Wu B. Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Pancreas 2012; 41: 1195-1205
  CrossrefPubMedGoogle Scholar
• 20 Distler M, Aust D, Weitz J et al. Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. Biomed Res Int 2014; 2014: 474905
  PubMedGoogle Scholar
• 21 Kanda M, Knight S, Topazian M et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 2013; 62: 1024-1033
  CrossrefPubMedGoogle Scholar
• 22 Tan MC, Basturk O, Brannon AR et al. GNAS and KRAS mutations define separate progression pathways in intraductal papillary mucinous neoplasm-associated carcinoma. J Am Coll Surg 2015; 220: 845-854
  CrossrefPubMedGoogle Scholar
• 23 Hosoda W, Sasaki E, Murakami Y et al. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. Virchows Arch 2015; 466: 665-674
  CrossrefPubMedGoogle Scholar
• 24 Singhi AD, Nikiforova MN, Fasanella KE et al. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res 2014; 20: 4381-4389
  CrossrefPubMedGoogle Scholar
• 25 Amato E, Molin MD, Mafficini A et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 2014; 233: 217-227
  CrossrefPubMedGoogle Scholar
• 26 Bournet B, Souque A, Senesse P et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. Endoscopy 2009; 41: 552-557
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Bournet B, Selves J, Grand D et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer. J Clin Gastroenterol 2015; 49: 50-56
  CrossrefPubMedGoogle Scholar
• 28 Komatsu H, Tanji E, Sakata N et al. A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes. PLoS One 2014; 9: e87875
  CrossrefPubMedGoogle Scholar
• 29 Ideno N, Ohtsuka T, Matsunaga T et al. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Pancreas 2015; 44: 311-320
  CrossrefPubMedGoogle Scholar
• 30 Aso T, Ohtsuka T, Matsunaga T et al. "High-risk stigmata" of the 2012 international consensus guidelines correlate with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2014; 43: 1239-1243
  CrossrefPubMedGoogle Scholar
• 31 Springer S, Wang Y, Dal Molin M et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology 2015; 149: 1501-1510
  CrossrefPubMedGoogle Scholar
• 32 Singhi AD, Zeh HJ, Brand RE et al. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. Gastrointest Endosc 2016; 83: 1107-1117
  CrossrefPubMedGoogle Scholar
• 33 Crippa S, Bassi C, Salvia R et al. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. Gut 2016; pii: DOI: 10.1136/gutjnl-2015-310162.
  PubMedGoogle Scholar